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Summary
Familial hemophagocytic lymphohistiocytosis (FHL) is
an autosomal recessive disorder characterized by the
early onset of overwhelming activation of T lymphocytes
and macrophages, invariably leading to death, in the
absence of allogeneic bone marrow transplantation. Us-
ing genomewide genetic linkage analysis, we analyzed a
group of 17 families with FHL and mapped a locus for
FHL to the proximal region of the long arm of chro-
mosome 10. Ten families showed no recombinationwith
three tightly linked markers, D10S1650 (LOD score
[Z]6.99), D10S556 (Z5.40), and D10S206 (Z
3.24), with a maximum multipoint LOD score of 11.22
at the D10S1650 locus. Haplotype analysis of these 10
families allowed us to establish D10S206 andD10S1665
as the telomeric and the centromeric flanking markers,
respectively. Heterogeneity analysis and haplotype in-
spection of the remaining families confirmed that in
seven families FHL was not linked to the 10q21-22 re-
gion, thus providing evidence for genetic heterogeneity
of this condition.
Introduction
Familial hemophagocytic lymphohistiocytosis (FHL;
MIM 267700), also known as “familial hemophagocytic
reticulosis,” “familial histiocytic reticulosis,” “familial
erythrophagocytic lymphohistiocytosis,” or “familial
histocytosis,” is a fatal inherited inflammatory disorder
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occurring during infancy or early childhood (Farquhar
and Claireaux 1952; Henter et al. 1998). It is inherited
as an autosomal recessive disease with an estimated fre-
quency, in Sweden, of 1 child/50,000 live births (Henter
et al. 1991b). FHL is one of the so-called hemophago-
cytic lymphohistiocytosis (HLH) syndromes, which are
characterized by hyperactivation and proliferation of T
cells and macrophages, associated with fever, edema, he-
patosplenomegaly, pancytopenia, coagulation abnor-
mality, liver dysfunction, and features of hemophago-
cytosis in bone marrow, lymph nodes, spleen, and liver
(Arico et al. 1996; Henter et al. 1998). In addition, CNS
involvement is frequent in these syndromes, with man-
ifestations ranging from confusion to severe seizures and
neurological impairment (Haddad et al. 1997). These
clinical characteristics are associated with the overpro-
duction, by T lymphocytes and macrophages, of several
cytokines, including interferon-g (INFg), and tumor ne-
crosis factor–a (Henter et al. 1991a). Chemotherapy and
immunosuppressive treatment are transiently effective
(Ste´phan et al. 1993), but FHL is invariably lethal unless
treated by bone marrow transplantation (Baker et al.
1997; Jabado et al. 1997). The primary cause of this
condition remains unknown.
Other causes of inherited HLH have been re-
ported—for example, Che´diak-Higashi syndrome (MIM
214500) (Bejaoui et al. 1989; Nagle et al. 1996; Barbosa
et al. 1997) and Griscelli syndrome (MIM 214450)
(Griscelli et al. 1978; Pastural et al. 1997), both asso-
ciated with partial albinism, and X-linked lymphopro-
liferative syndrome (XLP; MIM 308240) (Purtilo et al.
1975; Coffey et al. 1998; Sayos et al. 1998). Acquired
forms of HLH can also occur, associated with infections
(Risdall et al. 1979), autoimmune diseases, histiocytosis
X, or malignancies (Writing Group of the Histiocyte
Society 1987; Jaffe et al. 1993). Acquired HLH, how-
ever, usually occurs later in childhood. Diagnosis of FHL
thus depends on the association of both positive and
negative criteria, including the early occurrence and se-
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Figure 1 Pedigree of the 17 investigated FHL families. Age at disease onset, expressed in months, is indicated under the symbols for
affected individuals.
verity of the hemophagocytic syndrome, the occurrence
of relapse, evidence for autosomal recessive inheritance,
and the absence of associated albinism. On the basis of
these diagnostic features, we performed a whole-genome
linkage analysis in 17 multiplex and/or consanguineous
families with FHL, to map the FHL locus. We identified
a locus (FHL1) on chromosome 10q21-22 as well as
evidence for genetic heterogeneity of this condition.
Subjects and Methods
Patients and Families
Seventeen families referred either by the pediatric im-
munology and hematology unit at Hoˆpital Necker–
Enfants Malades (11 families) or by other clinical units
in France, the Netherlands, Germany, and Australia were
investigated. FHL was diagnosed on the basis of clinical,
immunological, biological, and genetic criteria, as dis-
cussed by Henter et al. (1998). Only families with either
recurrence of the disease or consanguinity were ana-
lyzed. Diagnostic features included fever, hepatospleno-
megaly, edema, and neurological abnormalities, accom-
panied by pancytopenia, liver cytolysis, hypertriglycer-
idemia, hypofibrinogenemia with evidence of hemo-
phagocytosis in bone marrow, liver, and cerebrospinal
fluid, and the presence of activated (HLADr) T lym-
phocytes in peripheral blood. None of the patients pre-
sented with either giant granulations in the cytoplasm
of hematopoietic cells or partial oculocutaneous albi-
nism. Diagnosis of either Che´diak-Higashi syndrome or
Griscelli syndrome was therefore excluded. In families
with male patients only, diagnosis of XLP was excluded
either by the absence of Epstein-Barr virus (EBV) ge-
nomic sequences in patients’ cells, as assessed by DNA
PCR amplification (in patients from family 32); absence
of EBV-specific IgM antibody response in patients whose
disease onset occurred at !6 mo of age (in patients from
families 21 and 32); or inheritance of different maternal
X chromosomes at the XLP locus (in the affected broth-
ers in family 45). This analysis was performed with poly-
morphic markers DXS1001 and DXS8044, which flank
the XLP locus within a 6-cM genetic region (Coffey et
al. 1998).
Onset of the disease is shown in figure 1. Onset oc-
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Figure 2 Results of multipoint LOD score analysis using GENEHUNTER. LOD17 was obtained under the hypothesis of homogeneity,
when all the FHL families were considered. LOD10 was obtained when only the 10 FHL families linked to chromosome 10 were considered.
HLOD17 shows the results of the LOD score analysis under the heterogeneity hypothesis, when all families were considered. The X-axis is the
genetic distance (in centimorgans) and the Y-axis is LOD score units. The positions of the genetic markers used in multipoint analysis are drawn
to scale on the X-axis. The centromere is located to the left of the graph and is not shown.
curred at age !6 mo in patients from 16 of the 17 fam-
ilies. Nine of the 17 families were consanguineous. These
families were of various origins: France, Portugal, north-
ern Africa, Australia, Mali, Germany, and Turkey. A
total of 86 subjects were investigated, 25 of whom were
affected.
Marker Analysis
After informed consent was obtained, blood samples
were collected from family members. DNA was ex-
tracted from leukocytes by standard methods. Poly-
morphic microsatellite markers were analyzed by use of
PCR and PAGE. Genotyping was performed either with
fluorescence-based techniques using an automated 373A
DNA sequencer with GENESCAN and GENOTYPER
software (Perkin-Elmer/Applied Biosystems) (Reed et al.
1994) or by radiolabeling using primers from the Ge´-
ne´thon collection (Dib et al. 1996).
Linkage Analysis
A genomewide linkage search for the FHL locus was
undertaken in the 17 families. The FASTLINK 2.2 pack-
age was used for genetic linkage analysis (Schaffer et al.
1994), and the GENEHUNTER 1.1 program (Kruglyak
et al. 1996) was used for multipoint linkage analysis.
Inheritance of FHL was considered to be autososomal
recessive, with an estimated frequency of 0.006 and com-
plete penetrance. Equal allele frequencies were used.
Marker-allele frequencies were assumed to be equal.
Heterogeneity tests were performed with the HOMOG
program (Ott 1983).
Results
Linkage Analysis
In view of the dysregulated T-cell and macrophage–
activation phenotype displayed by the FHL patients, we
first genotyped the families by using intragenic or linked
markers from regions containing candidate genes known
to be involved in the regulation of T-cell and macrophage
activation. We obtained no significant linkage in the fam-
ilies with the intragenic markers for the CTLA-4 (Po-
lymeropoulos et al. 1991) and interleukin 10 (Eskdale
and Gallagher 1995) genes or for the 3q13.3-q21,
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Table 1
LOD Scores between FHL1 Locus and Chromosome 10q21-22
Markers
MARKER
ALL 17
FAMILIES
10 LINKED
FAMILIES 7 RECOMBINANT FAMILIES
vmax Zmax vmax Zmax Z/v  .001 v/Z  2.00
D10S1743 .18 1.27 .05 3.30 16.45 .11
D10S1665 .13 2.85 .02 5.69 15.25 .10
D10S1650 .13 2.31 .00 6.99 14.44 .13
D10S556 .16 1.44 .00 5.40 15.19 .12
D10S206 .09 2.14 .00 3.24 3.31 .01
D10S219 .24 .81 .11 1.73 14.96 .09
D10S1686 .18 1.04 .17 1.12 15.25 .06
Figure 3 Pedigree of family 3 and haplotype analysis of markers of the 10q21-22 region, showing absence of linkage, in this FHL family,
to this region of chromosome 10.
21q22.1, and 11q23.3 regions, containing CD80/CD86,
the interleukin 10 receptor b chain, and the interleukin
10 receptor a chain genes, respectively (Selvakumar et
al. 1992). We then randomly screened the genome by
using 280 markers. We detected linkage between FHL1
and D10S201 on the long arm of human chromosome
10, with a maximum LOD score of 2.04 at maximum
recombination fraction (vmax).057, under the hypoth-
esis of homogeneity. Additional markers were used to
confirm linkage to this region (table 1). A maximum
LOD score of 2.85 (Zmax) was obtained for marker
D10S1665, at v.13.
Evidence for Genetic Heterogeneity
Results of the two-point LOD score analysis are
shown in table 1. Initial LOD-score analysis of each
individual pedigree indicated that, in 7 of the 17 families
studied, FHL disease occurrence did not map to chro-
mosome 10q21-22 (families 3, 8, 9, 16, 32, 45, and 54)
(not shown). The results from the other 10 families pro-
vided strong evidence for linkage with the markers in
this region (table 1). No recombination was detected
with D10S1650 (LOD score 6.99), D10S556 (LOD
score 5.40), and D10S206 (LOD score 3.24). The het-
erogeneity hypothesis was therefore tested by use of the
HOMOG program. As shown in table 2, for both tightly
linked markers D10S1650 (a.5; P.012) and
D10S556 (a.5; P.039), there was evidence of het-
erogeneity, indicating that, in approximately half of the
FHL families, there was a linkage to the FHL1 locus.
Formal multipoint analysis was performed by use of
the GENEHUNTER program and an overlapping set of
seven markers at a time. The LOD score (LOD17) was
negative over much of the region and reached a maxi-
mum of 0.58 distal to D10S556, under the hypothesis
of genetic homogeneity (fig. 2). In contrast, if a hetero-
geneity hypothesis was assumed, a maximum LOD score
(HLOD17) of 7.22 was attained at 0.8 cM proximal to
D10S1650. Multipoint analysis restricted to the set of
10 families in which FHL is associated with chromosome
10 showed FHL1 linkage to the D10S1650 marker, with
a maximum LOD score (LOD10) of 11.22.
In the seven other families, construction of haplotypes
in each family confirmed the presence of multiple re-
combination events within the region defined by the
tested markers. In the three consanguineous families, af-
fected individuals inherited different chromosomes from
their parents (as shown, for family 3, in fig. 3). In the
four other families, both affected individuals inherited
different haplotypes, or, conversely, both affected and
normal sibs inherited identical haplotypes from both
parents. Neither clinical nor pathological features of the
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Table 2
Heterogeneity Analysis: HOMOG Analysis Results
Marker a x2 P
D10S1743 .35 1.458 .114
D10S1665 .5 2.103 .074
D10S1650 .5 5.110 .012
D10S556 .5 3.087 .039
D10S556 .6 .855 .178
D10S219 1 0 .5
D10S1686 1 0 .5
disease, however, differed between the subgroups of
patients.
Haplotype Analysis of the Families with Linkage to
FHL1
The genetic interval was defined in the remaining 10
families by haplotype analysis. Figure 4 depicts the hap-
lotype segregation in seven of the pedigrees, including
the six consanguineous families. Recombination events
observed in affected individuals in families 4, 6, 25, 29,
and 34 define a critical region between markers
D10S206, telomerically, and D10S1665, centromeri-
cally. Thus, the FLH1 locus maps to the 13-cM interval
between these markers.
Discussion
FHL is one of the HLH syndromes, a heterogeneous
group of diseases characterized by hyperactivation of T
cells and macrophages (Farquhar et al. 1952; Arico et
al. 1996; Henter et al. 1998). FHL is one of four clearly
inherited entities in this group. It can be distinguished
from the other conditions that share autosomal recessive
inheritance—that is, Che´diak-Higashi syndrome and
Griscelli disease—since both of them cause partial al-
binism, as well as from XLP, by genetic segregation anal-
ysis and testing for the occurrence of EBV infection.
These criteria were used to demonstrate that the families
studied were not affected by these other inherited con-
ditions. FHL should also be distinguished from the ac-
quired HLH, often associated with viral infection, that
occurs as sporadic cases, usually later in childhood. To
avoid possible misdiagnosis of acquired forms, we re-
stricted linkage analysis in our study to consanguineous
and/or multiplex families with early onset of the disease.
Our data clearly establish the existence of a locus for
FHL, on the proximal long arm of chromosome 10
(FHL1), in a 13-cM candidate region between mar-
kers D10S206 and D10S1665. Assignment of the FHL1
locus to this region places it with a group of four dis-
orders previously mapped to the 10q21-22 region. These
disorders include autosomal recessive deafness 12 (MIM
601386), cardiomyopathy dilated 1C (MIM 601493),
congenital hypomyelinating neuropathy 1 (MIM
129010), and hemolytic anemia due to hexokinase de-
ficiency (MIM 142600). Several partial and complete
transcripts have been mapped to this region of chro-
mosome 10. These include ankyrin 3 (MIM 600465),
the b isoform of the catalytic subunit of the protein
phosphatase 3 (MIM 114106), annexin VII (MIM
186360), the calcium/calmodulin-dependent protein ki-
nase gamma (MIM 602123), and pore-forming protein
(MIM 170280). If, as hypothesized, FHL gene function
is involved in the negative regulation of T-cell activation,
none of these genes represent candidates for FHL. De-
tailed screening of the partial transcript sequences (Na-
tional Center for Biotechnology Information’s Genemap
98) that map to the critical region is being performed
to identify one of the genes involved in FHL.
This study shows that in only half the families is dis-
ease inheritance associated with the FHL1 locus, indi-
cating that FHL is a genetically heterogeneous disease.
Two-point and multipoint linkage analyses, HOMOG-
test analysis, and haplotype inspection of each individual
pedigree all showed evidence for heterogeneity, indicat-
ing the existence of at least a second locus for FHL.
Genetic heterogeneity is a feature of a number of in-
herited disorders (Jarman et al. 1997; Weiler et al. 1998).
However, because it is difficult to demonstrate significant
linkage when a disease phenotype is associated with sev-
eral loci, genetic heterogeneity is usually only described
once a first locus has been identified—sometimes in a
single family. The severity of FHL and its relatively low
incidence required the study of a large panel of families
of various origins, to increase the likelihood, during a
first linkage study, of detection of genetic heterogeneity.
In some disorders, genetic heterogeneity can be cor-
related with either phenotypic divergence or different
ethnic origins. In the case of FHL, the clinical and bi-
ological characteristics of the families in which the dis-
ease was linked to FHL1 were carefully compared with
those of the other families. None of the criteria, includ-
ing ethnic origin, age at onset, clinical presentation, bi-
ological features, or severity of the disease, enabled us
to differentiate these two groups of patients. However,
it is possible that there are more subtle differences, such
as different cytokine-production profiles or lymphocyte-
activation patterns. Study of additional families will be
required, to refine the localization of the FHL1 locus.
However, the absence of phenotypic criteria delineating
the two groups of families with FHL makes it difficult
to include those families in which only a short region
encompassing the FHL1 locus segregates with FHL.
Linkage studies are in progress in the families without
linkage to the FHL1 locus, to identify the putative sec-
ond locus for FHL. Ultimately, defining the genetic basis
of this condition should lead to both improvement in
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diagnosis and a better understanding of the pathogenesis
of HLH disorders.
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